Table 4. Effect of sequential versus simultaneous testing protocol on risk of HBV/HIV/HCV positivity.
| HBsAg |
Anti-HIV Ab |
Anti-HCV Ab |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing protocol | Number tested | Number positive | % | Number tested | Number positive | % | Number tested | Number positive | % | ||
| Sequential | |||||||||||
| Male | 32 826 | 1 418 | 4.32 | 31 255 | 1 | 0.003 | 31 107 | 52 | 0.17 | ||
| Female | 2 350 | 38 | 1.62 | 2 216 | 0 | 0 | 2 281 | 0 | 0 | ||
| All | 35 176 | 1 456 | 4.14 | 33 471 | 1 | 0.003 | 33 388 | 52 | 0.16 | ||
| Simultaneous | |||||||||||
| Male | 26 914 | 1 133 | 4.21 | 26 914 | 3 | 0.01 | 26 914 | 151 | 0.56 | ||
| Female | 2 864 | 115 | 4.02 | 2 864 | 0 | 0 | 2 864 | 5 | 0.17 | ||
| All | 29 778 | 1 248 | 4.19 | 29 778 | 3 | 0.01 | 29 778 | 156 | 0.52 | ||
| RR = 0.99a 95% CI: 0.92–1.06 | RR = 0.30a 95% CI: 0.03–2.85 | RR = 0.33a 95% CI: 0.22–0.41 | |||||||||
Ab, antibody; CI, confidence interval; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; RR, relative risk. a Risk is for sequential versus simultaneous.